Two Cases of Hypersensitivity Reactions Caused by Human Serum Albumin During Therapeutic Plasma Exchange
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Iso-oncotic human serum albumin (HSA) is the primary replacement fluid of choice during therapeutic plasma exchange (TPE). Hypersensitivity reactions to HSA are rare, but require proper evaluation and management. In this article, we report two cases of hypersensitivity reactions to 5% HSA during TPE and discuss strategies to address this problem. The first case was a 60-year-old female patient, who was scheduled for TPE for treatment of recurrent focal segmental glomerulosclerosis after ABO-incompatible kidney transplantation. She developed a pruritic rash on her entire body during the first two sessions of TPE using 5% HSA. The third session was conducted using 500 mL normal saline, 1,000 mL 10% pentastarch, and 750 mL 5% HSA, where she eventually developed a pruritic rash when HSA was infused. There were no adverse events during the fourth and fifth session when fresh frozen plasma was used in place of HSA. The second case was a 50-year-old male patient diagnosed with optic neuritis, who was admitted for five sessions of TPE. The patient developed a pruritic rash on his entire body during the first session of TPE using 5% HSA. The patient experienced no adverse events during the following four sessions using fresh frozen plasma. Certain elements contained in HSA, such as albumin aggregates, prekallikrein activator, and caprylate-modified albumin, might be the reason for these hypersensitivity reactions. Careful selection of alternative replacement fluids is important to avoid premature termination of TPE procedures and secure optimal treatment options for patients.
Abstract
Iso-oncotic human serum albumin (HSA) is the primary replacement fluid of choice during therapeutic plasma exchange (TPE). Hypersensitivity reactions to HSA are rare, but require proper evaluation and management. In this article, we report two cases of hypersensitivity reactions to 5% HSA during TPE and discuss strategies to address this problem. The first case was a 60-year-old female patient, who was scheduled for TPE for treatment of recurrent focal segmental glomerulosclerosis after ABO-incompatible kidney transplantation. She developed a pruritic rash on her entire body during the first two sessions of TPE using 5% HSA. The third session was conducted using 500 mL normal saline, 1,000 mL 10% pentastarch, and 750 mL 5% HSA, where she eventually developed a pruritic rash when HSA was infused. There were no adverse events during the fourth and fifth session when fresh frozen plasma was used in place of HSA. The second case was a 50-year-old male patient diagnosed with optic neuritis, who was admitted for five sessions of TPE. The patient developed a pruritic rash on his entire body during the first session of TPE using 5% HSA. The patient experienced no adverse events during the following four sessions using fresh frozen plasma. Certain elements contained in HSA, such as albumin aggregates, prekallikrein activator, and caprylate-modified albumin, might be the reason for these hypersensitivity reactions. Careful selection of alternative replacement fluids is important to avoid premature termination of TPE procedures and secure optimal treatment options for patients.
참고문헌 (22)
- McLeod BC, "Therapeutic apheresis : use of human serum albumin, fresh frozen plasma and cryosupernatant plasma in therapeutic plasma exchange", Best Pract Res Clin Haematol, 19, pp.157~167 (2006)
- Pandey S, "Adverse effects of plasma transfusion", Transfusion, 52(S1), pp.65S~79S (2012)
- Fung MK, "Technical manual", pp.678~680 (2014), American Association of Blood Banks
- Stafford CT, "Anaphylaxis to human serum albumin", Ann Allergy, 61, pp.85~88 (1988)
- Komericki P, "Near-fatal anaphylaxis caused by human serum albumin in fibrinogen and erythrocyte concentrates", Anaesthesia, 69, pp.176~178 (2014)
- Fujita A, "Anaphylactoid shock in a patient following 5% human serum albumin infusion during off-pump coronary artery bypass grafting", J Anesth, 21, pp.396~398 (2007)
- Ring J, "Anaphylactoid reactions to infusions of plasma protein and human serum albumin. Role of aggregated proteins and of stabilizers added during production", Clin Allergy, 9, pp.89~97 (1979)
- Beavers C, "Severe intraoperative albumin transfusion reaction and review of the literature", Lab Med, 44, pp.e129~e131 (2013)
- 정소윤, "알부민에 의한 아나필락시스를 보인 소아에서 성공적인탈감작 적용 1예", Allergy Asthma & Respiratory Disease, 5(2), pp.117~120 (2017), 대한 소아알레르기 호흡기학회[DOI]
- McLeod BC, "Plasma and plasma derivatives in therapeutic plasmapheresis", Transfusion, 52(S1), pp.38S~44S (2012)
- Hirayama F, "Current understanding of allergic transfusion reactions : incidence, pathogenesis, laboratory tests, prevention and treatment", Br J Haematol, 160, pp.434~444 (2013)
- Matejtschuk P, "Production of human albumin solution : a continually developing colloid", Br J Anaesth, 85, pp.887~895 (2000)
- Heinonen J, "Correlation of hypotensive effect of plasma protein fraction with prekallikrein activator activity : a clinical study in patients having open-heart surgery", Ann Thorac Surg, 33, pp.244~249 (1982)
- Alving BM, "Hypotension associated with prekallikrein activator(Hageman-factor fragments)in plasma protein fraction", N Engl J Med, 299, pp.66~70 (1978)
- Yu MW, "Stabilization of human albumin by caprylate and acetyltryptophanate", Vox Sang, 47, pp.28~40 (1984)
- Hossaini AA, "Experimental induction of caprylate-dependent albumin antibodies", Transfusion, 17, pp.54~58 (1977)
- Hafer C, "Membrane versus centrifuge-based therapeutic plasma exchange : a randomized prospective crossover study", Int Urol Nephrol, 48, pp.133~138 (2016)
- Madore F, "Plasmapheresis. Technical aspects and indications", Crit Care Clin, 18, pp.375~392 (2002)
- Myburgh JA, "Resuscitation fluids", N Engl J Med, 369, pp.1243~1251 (2013)
- Barron ME, "A systematic review of the comparative safety of colloids", Arch Surg, 139, pp.552~563 (2004)
- Mitra S, "Are all colloids same? How to select the right colloid", Indian J Anaesth, 53, pp.592~607 (2009)
- Harm S, "Removal of stabilizers from human serum albumin by adsorbents and dialysis used in blood purification", PLoS One, 13, pp.e0191741~ (2018)